Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.54 | 46.50 | 47.32 | 43.05 | 44.74 | 45.14 | 29.61 | 43.04 | 47.17 | 46.91 | 60.65 | 47.90 |
| Expenses | 38.89 | 41.60 | 41.57 | 39.60 | 39.43 | 38.43 | 31.22 | 38.43 | 42.01 | 42.53 | 55.22 | 43.57 |
| Operating Profit | 4.65 | 4.90 | 5.75 | 3.45 | 5.31 | 6.71 | -1.61 | 4.61 | 5.16 | 4.38 | 5.43 | 4.33 |
| OPM % | 10.68% | 10.54% | 12.15% | 8.01% | 11.87% | 14.86% | -5.44% | 10.71% | 10.94% | 9.34% | 8.95% | 9.04% |
| Other Income | 0.55 | 0.83 | 0.57 | 0.59 | 0.29 | 0.14 | 5.23 | 0.47 | 0.37 | 0.53 | 1.74 | 0.86 |
| Interest | 0.91 | 0.65 | 1.89 | 0.71 | 1.04 | 0.76 | 0.65 | 1.15 | 0.99 | 0.97 | 0.38 | 0.83 |
| Depreciation | 1.82 | 1.80 | 1.77 | 1.77 | 2.61 | 2.21 | 0.48 | 1.80 | 1.86 | 1.83 | 1.73 | 1.79 |
| Profit before tax | 2.47 | 3.28 | 2.66 | 1.56 | 1.95 | 3.88 | 2.49 | 2.13 | 2.68 | 2.11 | 5.06 | 2.57 |
| Tax % | 39.68% | 38.11% | 22.93% | 48.72% | 53.85% | 24.74% | 25.30% | 24.88% | 21.27% | 22.27% | 12.06% | 28.40% |
| Net Profit | 1.47 | 2.03 | 2.04 | 0.80 | 0.91 | 2.92 | 1.87 | 1.60 | 2.12 | 1.64 | 4.45 | 1.85 |
| EPS in Rs | 1.19 | 1.90 | 1.68 | 1.06 | 1.15 | 2.73 | 1.90 | 1.59 | 1.97 | 1.61 | 2.85 | 1.56 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 125 | 113 | 115 | 141 | 179 | 163 | 198 | 203 |
| Expenses | 105 | 106 | 93 | 91 | 117 | 156 | 148 | 177 | 183 |
| Operating Profit | 17 | 20 | 20 | 24 | 24 | 24 | 14 | 21 | 19 |
| OPM % | 14% | 16% | 17% | 21% | 17% | 13% | 9% | 10% | 10% |
| Other Income | 4 | 2 | 1 | 2 | 2 | 2 | 6 | 3 | 4 |
| Interest | 1 | 1 | 2 | 2 | 3 | 6 | 4 | 5 | 3 |
| Depreciation | 2 | 2 | 3 | 6 | 6 | 7 | 7 | 7 | 7 |
| Profit before tax | 18 | 18 | 16 | 18 | 17 | 13 | 10 | 12 | 12 |
| Tax % | 31% | 26% | 26% | 18% | 14% | 27% | 34% | 18% | |
| Net Profit | 12 | 13 | 12 | 15 | 15 | 9 | 7 | 10 | 10 |
| EPS in Rs | 10.28 | 10.88 | 9.93 | 12.20 | 11.73 | 8.60 | 5.59 | 7.11 | 7.99 |
| Dividend Payout % | 10% | 5% | 10% | 8% | 9% | 12% | 18% | 14% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 12% | 12% | 25% | ||
| Compounded Profit Growth | % | -4% | -13% | 14% | ||
| Stock Price CAGR | 6% | -11% | -21% | 7% | ||
| Return on Equity | % | 6% | 4% | 4% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 14 |
| Reserves | 75 | 109 | 121 | 134 | 181 | 194 | 200 | 262 |
| Borrowings | 12 | 11 | 19 | 26 | 26 | 31 | 34 | 49 |
| Other Liabilities | 38 | 49 | 42 | 53 | 59 | 56 | 50 | 47 |
| Total Liabilities | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 372 |
| Fixed Assets | 24 | 34 | 90 | 92 | 93 | 92 | 87 | 85 |
| CWIP | 15 | 40 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Other Assets | 97 | 107 | 104 | 133 | 186 | 203 | 210 | 287 |
| Total Assets | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 372 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 4 | 13 | 13 | 4 | -6 | -7 | -8 | -33 |
| Cash from Investing Activity | -15 | -37 | -18 | -8 | -6 | -6 | -1 | -3 |
| Cash from Financing Activity | -4 | 19 | 6 | 4 | 29 | 6 | -1 | 64 |
| Net Cash Flow | -14 | -5 | 1 | -0 | 17 | -6 | -11 | 28 |
| Free Cash Flow | -11 | -25 | -5 | -4 | -13 | -13 | -10 | -38 |
| CFO/OP | 48% | 88% | 88% | 30% | -13% | -16% | -47% | -150% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 129 | 145 | 170 | 200 | 169 | 112 | 155 | 151 |
| Inventory Days | 67 | 78 | 27 | 188 | 228 | 234 | 268 | 251 |
| Days Payable | 134 | 173 | 169 | 302 | 241 | 154 | 184 | 144 |
| Cash Conversion Cycle | 62 | 51 | 28 | 86 | 156 | 193 | 239 | 259 |
| Working Capital Days | 116 | 130 | 126 | 147 | 156 | 123 | 186 | 193 |
| ROCE % | 16% | 13% | 12% | 10% | 8% | 6% | 6% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 43.21% | 43.21% | 43.21% | 42.99% | 42.99% | 42.99% | 43.16% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% |
| FIIs | 0.22% | 0.22% | 0.12% | 0.06% | 0.06% | 0.06% | 0.12% | 0.00% | 0.05% | 0.02% | 0.10% | 0.07% |
| DIIs | 0.20% | 0.67% | 0.99% | 1.17% | 1.17% | 0.87% | 0.69% | 0.64% | 0.59% | 0.44% | 0.00% | 0.40% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% | 0.06% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| Public | 56.38% | 55.90% | 55.69% | 55.78% | 55.79% | 56.04% | 55.99% | 58.83% | 58.84% | 59.02% | 59.39% | 59.01% |
| No. of Shareholders | 9,419 | 10,252 | 10,639 | 10,652 | 10,792 | 10,576 | 10,435 | 10,808 | 11,177 | 10,967 | 10,806 | 11,047 |
Fundamentals
Market Cap₹ 434 Cr.
Current Price₹ 322
Stock P/E40.0
Book Value₹ 203
ROCE5.82 %
ROE3.95 %
Dividend Yield0.31 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)25%
Compounded Profit Growth (TTM)14%
Consolidated figures.
Valuation
Market capRs 405 Cr
Enterprise valueRs 421 Cr
P/E (TTM)37.37x
Price to book1.96x
Price to sales2.00x
EV / EBITDA18.48x
EV / EBIT27.03x
EV / sales2.08x
Earnings yield2.68%
Dividend yield0.31%
P/E, 3-year average51.12x
P/B, 3-year average4.00x
P/E, 5-year average44.75x
P/B, 5-year average3.75x
Profitability
Operating margin (excl. other income)13.11%
Operating margin (incl. other income)14.41%
EBITDA margin11.25%
Pre-tax margin6.13%
Net profit margin5.35%
Net margin, latest quarter4.43%
ROE5.46%
ROCE8.20%
ROA3.81%
ROE, 3-year average8.29%
ROCE, 3-year average10.34%
ROA, 3-year average5.60%
ROE, 5-year average9.44%
ROCE, 5-year average11.99%
ROA, 5-year average6.33%
ROIC (approx.)5.07%
Tax rate27.37%
Other income / net worth1.13%
Growth
Sales growth (latest year)27.29%
Profit growth (latest year)-26.35%
Sales CAGR, 3 years16.74%
Sales CAGR, 5 years7.90%
Profit CAGR, 3 years-3.41%
Profit CAGR, 5 years-1.90%
Sales growth QoQ-21.02%
Profit growth QoQ-45.08%
Sales growth YoY (latest quarter)11.29%
Profit growth YoY (latest quarter)-1.40%
Per share
EPS (TTM)Rs 8.53
EPS (latest year)Rs 8.60
EPS (latest quarter)Rs 1.67
EPS, 3-year averageRs 10.84
EPS, 5-year averageRs 10.67
Book value per shareRs 162.79
Sales per shareRs 159.37
Cash flow per shareRs -5.30
Free cash flow per shareRs -29.89
Dividend per share (latest year)Rs 1.00
Dividend per share, 3-year averageRs 1.00
Dividend per share, 5-year averageRs 0.90
Dividends
Dividend payout11.62%
Dividend payout, 3-year average9.43%
Dividend payout, 5-year average8.59%
Efficiency
Asset turnover0.61x
Fixed asset turnover1.95x
Inventory turnover1.85x
Inventory days197 days
Debtor days112 days
Debtors turnover3.24x
Creditor days144 days
Cash conversion cycle259 days
Working capital days193 days
Leverage
Total debtRs 31 Cr
Cash and bankRs 15 Cr
Net debtRs 16 Cr
Debt to equity0.15x
Net debt / EBITDA0.72x
Interest coverage4.92x
Current ratio (filing 2026-03-31)2.54x
Quick ratio (filing 2026-03-31)1.75x
Trade payables (filing 2026-03-31)Rs 40 Cr
Owners' fund to total sources70.27%
Debt to assets10.56%
Cash flow
Cash from Operating Activity (latest year)Rs -7 Cr
Cash from Investing Activity (latest year)Rs -6 Cr
Cash from Financing Activity (latest year)Rs 6 Cr
Net Cash Flow (latest year)Rs -6 Cr
Free cash flow (latest year)Rs -38 Cr
FCFE (approx.: FCF + change in debt)Rs -33 Cr
Cash from ops / profit, 5 years-0.89x
Statement figures
Net sales (TTM)Rs 203 Cr
Net sales (latest year)Rs 179 Cr
Sales (latest quarter)Rs 48 Cr
Operating profit excl. other income (latest year)Rs 24 Cr
Operating profit (latest quarter)Rs 4 Cr
Other income (TTM)Rs 4 Cr
EBITDA (TTM)Rs 23 Cr
PBDT (TTM)Rs 20 Cr
Profit before tax (TTM)Rs 12 Cr
Tax (latest year)Rs 4 Cr
Net profit (TTM)Rs 11 Cr
Net profit (latest year)Rs 11 Cr
Net profit (latest quarter)Rs 2 Cr
Depreciation (TTM)Rs 7 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 3 Cr
Cost of goods sold (latest year)Rs 110 Cr
Total expenditure (latest year)Rs 156 Cr
Total income (latest year)Rs 182 Cr
Share capitalRs 13 Cr
ReservesRs 194 Cr
Shareholders' fundsRs 207 Cr
Total assetsRs 295 Cr
Net blockRs 92 Cr
ReceivablesRs 55 Cr
InventoryRs 59 Cr
Other liabilitiesRs 56 Cr
Shares outstanding (crore)1.27
Ownership
Promoter holding40.46% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 37.4 is at the 12th percentile of its own 5.4-year range
(median 60.9, low 27.4, high 112.6).
P/B 1.96 is at the 11th percentile (median 5.17).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | MEDICAMEQ | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +3.9% | -2.8% | +6.7 pts |
| 1 month | +19.1% | -6.8% | +25.9 pts |
| 3 months | +22.1% | -7.6% | +29.7 pts |
| 6 months | +42.7% | +0.4% | +42.3 pts |
| 1 year | -2.0% | -9.9% | +7.9 pts |
| 2 years | -29.9% | -13.6% | -16.3 pts |
| 3 years | -51.4% | +14.2% | -65.6 pts |
| 5 years | -46.8% | +27.9% | -74.7 pts |
Red flags
F-score 3 of 8| explain | Weak cash conversion Cash from operations was -22% of net profit over the last 3 years |
| look | On NSE surveillance On NSE surveillance: ESM |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹48 Cr +11.3% vs Jun 2025.
Net profit ₹2 Cr +15.6%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-18 | Dividend - Re 1 Per Share | |
| 2025-09-19 | Dividend - Re 1 Per Share | |
| 2024-09-19 | Annual General Meeting/Dividend - Re 1 Per Share | |
| 2023-09-20 | Annual General Meeting/Dividend - Re 1 Per Share | |
| 2022-09-19 | Annual General Meeting/Dividend - Re 1 Per Share |
| Date | Type | What it says |
|---|---|---|
| 2026-09-30 | Trading Plan under PIT | Trading Plan pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
ESM: stage 1